Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) General Counsel David O. Watson Sells 5,000 Shares

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) General Counsel David O. Watson sold 5,000 shares of the business's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $18.77, for a total value of $93,850.00. Following the completion of the transaction, the general counsel now owns 133,730 shares in the company, valued at $2,510,112.10. The trade was a 3.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Apellis Pharmaceuticals Trading Down 0.4%

Shares of APLS traded down $0.07 during mid-day trading on Friday, reaching $17.69. 2,092,818 shares of the company's stock traded hands, compared to its average volume of 2,347,603. The stock has a market cap of $2.22 billion, a P/E ratio of -9.88 and a beta of 0.68. The stock's 50-day moving average is $18.18 and its two-hundred day moving average is $24.69. Apellis Pharmaceuticals, Inc. has a 12 month low of $16.10 and a 12 month high of $42.47. The company has a debt-to-equity ratio of 2.76, a current ratio of 4.08 and a quick ratio of 3.62.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported ($0.74) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.38). The business had revenue of $149.90 million for the quarter, compared to the consensus estimate of $197.61 million. Apellis Pharmaceuticals had a negative net margin of 28.83% and a negative return on equity of 99.19%. The company's quarterly revenue was down 3.2% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.54) EPS. Research analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently commented on APLS shares. Robert W. Baird decreased their target price on Apellis Pharmaceuticals from $55.00 to $47.00 and set an "outperform" rating on the stock in a research report on Thursday, May 8th. Needham & Company LLC decreased their target price on Apellis Pharmaceuticals from $40.00 to $29.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Mizuho decreased their target price on Apellis Pharmaceuticals from $30.00 to $20.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 14th. Citigroup decreased their target price on Apellis Pharmaceuticals from $49.00 to $41.00 and set a "buy" rating on the stock in a research report on Thursday, May 22nd. Finally, Scotiabank decreased their target price on Apellis Pharmaceuticals from $28.00 to $20.00 and set a "sector perform" rating on the stock in a research report on Thursday, May 8th. Nine analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $40.05.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. GF Fund Management CO. LTD. grew its stake in shares of Apellis Pharmaceuticals by 21.9% during the first quarter. GF Fund Management CO. LTD. now owns 3,185 shares of the company's stock valued at $70,000 after buying an additional 573 shares during the last quarter. Xponance Inc. grew its stake in shares of Apellis Pharmaceuticals by 5.6% during the fourth quarter. Xponance Inc. now owns 14,072 shares of the company's stock valued at $449,000 after buying an additional 749 shares during the last quarter. EverSource Wealth Advisors LLC grew its stake in shares of Apellis Pharmaceuticals by 2,707.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company's stock valued at $25,000 after buying an additional 758 shares during the last quarter. Baird Financial Group Inc. grew its stake in shares of Apellis Pharmaceuticals by 1.6% during the first quarter. Baird Financial Group Inc. now owns 55,529 shares of the company's stock valued at $1,214,000 after buying an additional 864 shares during the last quarter. Finally, Woodline Partners LP boosted its holdings in shares of Apellis Pharmaceuticals by 0.5% in the fourth quarter. Woodline Partners LP now owns 189,477 shares of the company's stock valued at $6,046,000 after purchasing an additional 913 shares during the period. Institutional investors own 96.29% of the company's stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).